Amneal Pharmaceuticals (AMRX) investor relations material

Strategic overview and recent performance

• Achieved strong 2025 results, exceeding guidance and setting a positive outlook for 2026 and beyond.

• Diversified business through acquisitions, new product launches, and expanded R&D in complex areas since 2019.

• Affordable Medicines Group (generics, injectables, biosimilars) grew 5% over five years, with expectations for high single-digit growth ahead.

• Specialty segment saw robust growth, driven by successful launches like CREXONT and Brekiya.

• Won industry recognition as Best Company to Work For, highlighting positive culture.

Segment performance and growth drivers

• Retail generics business is expanding, supported by new ophthalmics, transdermal, and inhalation product launches.

• Injectables pipeline includes complex products and ready-to-use bags, with growth expected from upcoming approvals.

• Biosimilars segment poised for acceleration with denosumab launch in late 2026 and XOLAIR in 2027, plus potential M&A to expand pipeline.

• CREXONT outperformed expectations, converting 80% of ER patients and projected to reach $300M–$500M in peak sales.

• Brekiya auto-injector for headaches exceeded uptake forecasts, with peak sales estimated at $50M–$100M.

Operational changes and profitability

• De-emphasized low-margin distribution in AvKARE, focusing on profitable VA/DoD channels, improving EBITDA despite lower revenues.

• Margin expansion expected in biosimilars due to regulatory changes and vertical integration, with 100 basis points improvement projected for 2026.

• Capital allocation prioritizes R&D investment ($180M–$200M) and vertical integration for biosimilars.

• International growth targeted through direct markets like India and partnerships in Europe and other regions.